GABA A receptor agonist - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in GABA A receptor agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
GABA A receptor agonist: Overview
Type-A ?-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.
Report Highlights
This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA A receptor agonist Emerging Drugs
Further product details are provided in the report……..
GABA A receptor agonist: Therapeutic Assessment
This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:
GABA A receptor agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.
GABA A receptor agonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in GABA A receptor agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
GABA A receptor agonist: Overview
Type-A ?-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence GABA A receptor agonist R&D. The therapies under development are focused on novel approaches for GABA A receptor agonist.
This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA A receptor agonist Emerging Drugs
- Ganaxolone: Marinus Pharmaceuticals
- Padsevonil: UCB Biopharma
Further product details are provided in the report……..
GABA A receptor agonist: Therapeutic Assessment
This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on GABA A receptor agonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
GABA A receptor agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.
GABA A receptor agonist Report Insights
- GABA A receptor agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing GABA A receptor agonist drugs?
- How many GABA A receptor agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for GABA A receptor agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA A receptor agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for GABA A receptor agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Marinus Pharmaceuticals
- UCB Biopharma
- Confluence Pharmaceuticals
- Cerevel Therapeutics
- Sichuan Haisco Pharmaceutical
- Ovid Therapeutics
- Ganaxolone
- Padsevonil
- Acamprosate
- Darigabat
- Ciprofol
- OV101
Introduction
Executive Summary
GABA A receptor agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
GABA A receptor agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
GABA A receptor agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
GABA A receptor agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Padsevonil: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Darigabat: Cerevel Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
GABA A receptor agonist Key Companies
GABA A receptor agonist Key Products
GABA A receptor agonist- Unmet Needs
GABA A receptor agonist- Market Drivers and Barriers
GABA A receptor agonist- Future Perspectives and Conclusion
GABA A receptor agonist Analyst Views
GABA A receptor agonist Key Companies
Appendix
Executive Summary
GABA A receptor agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
GABA A receptor agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
GABA A receptor agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
GABA A receptor agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Padsevonil: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Darigabat: Cerevel Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
GABA A receptor agonist Key Companies
GABA A receptor agonist Key Products
GABA A receptor agonist- Unmet Needs
GABA A receptor agonist- Market Drivers and Barriers
GABA A receptor agonist- Future Perspectives and Conclusion
GABA A receptor agonist Analyst Views
GABA A receptor agonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for GABA A receptor agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for GABA A receptor agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for GABA A receptor agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for GABA A receptor agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products